Clinicopathologic Conference, Cerebral Amyloid Angiopatny-Related Inflammation
NEJM 385:358-368, Case 22-2021, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation
JAMA Neurol 73:197-202, Auriel, E.,et al, 2016
A Case of Subacute Cognitive Decline in a 76-year-old Man
Neurol 87:e124-e128, MacLellan, A.,et al, 2016
Inflammatory Cerebral Amyloid Angiopathy, Amyloid-B-Related Angiitis, and Primary Angiitis of the Central Nervous System
Stroke 46:e210-e213, Moussaddy, A.,et al, 2015
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Primary Central Nervous System Vasculitis with Prominent Leptomeningeal Enhancement
Arthritis Rheum:58:595-603, Salvarani, C.,et al, 2008
Course of Cerebral Amyloid Angiopathy-Related Inflammation
Neurol 68:1411-1416, Kinnecom,C.,et al, 2007
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
Clinical Manifestations of Cerebral Amyloid Angiopathy-Related Inflammation
Ann Neurol 55:250-256, Eng,J.A.,et al, 2004
An Open-Label Trial of Combination Therapy With Interferon B-1a and Oral Methotrexate in MS
Neurol 58:314-317, Calabresi,P.A.,et al, 2002
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Current Immunotherapy in Multiple Sclerosis
Immunology and Cell Biology 76:55-64, Bashir,K.&Whitaker,J.N., 1998
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997